Mirum Pharmaceuticals (MIRM) stockholders back 2026 directors, auditor and pay package
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Mirum Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 15, 2026. As of the April 20, 2026 record date, 60,977,841 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class I directors—Lon Cardon, William Fairey, and Timothy Walbert—to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Mirum’s stockholders also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 60,977,841 shares
Votes for auditor ratification: 49,993,514 votes
Votes for say-on-pay: 44,534,575 votes
+3 more
6 metrics
Shares entitled to vote
60,977,841 shares
Common stock outstanding as of April 20, 2026 record date
Votes for auditor ratification
49,993,514 votes
Ernst & Young LLP as auditor for year ending December 31, 2026
Votes for say-on-pay
44,534,575 votes
Advisory approval of named executive officer compensation
Votes for Lon Cardon
39,587,327 votes
Election as Class I director
Votes for William Fairey
40,266,848 votes
Election as Class I director
Votes for Timothy Walbert
32,329,718 votes
Election as Class I director
Key Terms
Broker Non-Votes, independent registered public accounting firm, Advisory Vote on Executive Compensation, Audit Committee
4 terms
Broker Non-Votes financial
"Votes For | | Votes Withheld | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Advisory Vote on Executive Compensation financial
"Proposal 3. Advisory Vote on Executive Compensation"
A non-binding shareholder vote allowing investors to approve or reject the pay packages and compensation policies for a company’s top executives. It matters because the outcome tells the board whether owners are satisfied with executive pay and can prompt changes in policy or leadership much like a customer survey prompts a company to adjust its product — signaled approval can support management credibility, while rejection may increase scrutiny and affect investor confidence.
Audit Committee financial
"selection by the Audit Committee of the Company’s Board of Directors"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
FAQ
What did Mirum Pharmaceuticals (MIRM) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing three Class I directors, ratifying Ernst & Young LLP as independent auditor for 2026, and approving an advisory resolution on executive compensation. All three proposals received sufficient support to pass at the meeting.
Which directors were elected at Mirum Pharmaceuticals’ 2026 annual meeting?
Stockholders elected Lon Cardon, William Fairey, and Timothy Walbert as Class I directors. Each director will serve until Mirum Pharmaceuticals’ 2029 annual meeting of stockholders, and until a successor is duly elected and qualified or earlier death, resignation, or removal.
Was Mirum Pharmaceuticals’ auditor ratified for the 2026 fiscal year?
Yes. Stockholders ratified the Audit Committee’s selection of Ernst & Young LLP as Mirum Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 49,993,514 votes for, 5,674 against, and 30,192 abstentions.
Did Mirum Pharmaceuticals (MIRM) stockholders approve executive compensation on an advisory basis?
Yes. Stockholders approved, on an advisory basis, the compensation of Mirum Pharmaceuticals’ named executive officers. The proposal received 44,534,575 votes for, 1,866,719 votes against, 13,247 abstentions, and 3,614,839 broker non-votes as reported in the meeting results.
What were the vote results for Mirum director Timothy Walbert’s election?
For director Timothy Walbert, stockholders cast 32,329,718 votes for and 14,084,823 votes withheld, with 3,614,839 broker non-votes. Despite the higher number of withheld votes relative to other nominees, he was elected as a Class I director through the 2029 annual meeting.